Recombinant AAV vectors have gained importance as a gene delivery method for innovative gene therapy products. However, the existing batch production process using human embryonic kidney (HEK) 293 cells suffers from inefficiency and high costs. This project focussed on developing this process, resulting to the successful development of a scalable, batch transient transfection process for AAV production in HEK293 cells.
The development of a scalable process suitable for multiple HEK293 lines has laid the foundation for future multi-omics studies aimed at uncovering host cell pathways involved in AAV production and further improving HEK bioprocessing.
